Form 4: Larimar Therapeutics Chief Medical Officer Acquires Shares and Options
SEC Form 4 Filing
Larimar Therapeutics' Chief Medical Officer, Russell Clayton, acquired 23,306 shares of common stock and 139,838 stock options on January 22, 2025.
Summary
- On January 22, 2025, Russell Clayton, the Chief Medical Officer of Larimar Therapeutics, acquired 23,306 shares of common stock through restricted stock units (RSUs).
- Each RSU represents a contingent right to receive one share of Larimar's common stock upon settlement.
- Additionally, Mr. Clayton acquired 139,838 stock options with an exercise price of $3.46 per share.
- The stock options vest 25% on January 22, 2026, and the remaining 75% vest monthly over the following 36 months, contingent on continued service with the company.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications.
Positives
- The acquisition of shares and options by a key executive like the Chief Medical Officer can be seen as a positive sign of confidence in the company's future.
Industry Context
This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.
Comparison to Industry Standards
- Stock option grants and restricted stock units are common forms of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
- The vesting schedule of the options, with a 25% cliff vesting after one year followed by monthly vesting, is a typical structure for such grants.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment as it indicates confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| 01/22/2025 | Date of the transaction where the shares and options were acquired. |
| 01/22/2026 | Date when 25% of the stock options vest. |
| 01/24/2025 | Date the form was signed by Jennifer Johansson, Attorney-in-fact. |
| 01/22/2035 | Expiration date of the stock options. |
Keywords
Larimar Therapeutics, LRMR, Russell Clayton, Chief Medical Officer, Stock Options, Restricted Stock Units, RSU, Share Acquisition, Executive Compensation, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.